Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Current Leases (2016 - 2018)

Gsk has reported Current Leases over the past 3 years, most recently at $30.9 million for Q4 2018.

  • Quarterly results put Current Leases at $30.9 million for Q4 2018, up 1.13% from a year ago — trailing twelve months through Dec 2018 was $30.9 million (up 1.13% YoY), and the annual figure for FY2018 was $32.1 million, up 8.18%.
  • Current Leases for Q4 2018 was $30.9 million at Gsk, up from $30.5 million in the prior quarter.
  • Over the last five years, Current Leases for GLAXF hit a ceiling of $30.9 million in Q4 2018 and a floor of $28.6 million in Q4 2016.
  • Median Current Leases over the past 3 years was $30.5 million (2017), compared with a mean of $30.0 million.
  • Biggest five-year swings in Current Leases: grew 6.79% in 2017 and later rose 1.13% in 2018.
  • Gsk's Current Leases stood at $28.6 million in 2016, then increased by 6.79% to $30.5 million in 2017, then grew by 1.13% to $30.9 million in 2018.
  • The last three reported values for Current Leases were $30.9 million (Q4 2018), $30.5 million (Q4 2017), and $28.6 million (Q4 2016) per Business Quant data.